Uroxatral Tablet, Extended Release
Product Images NDC 59212-200

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Uroxatral (NDC 59212-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanz Pharma (us) Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle 100tablets

This appears to be a label for a medication called "alfuzosin HCl" with a strength of 10 milligrams. The medication is made by a company called Concordia, and the brand name is Uroxatral. The label warns against chewing or crushing the tablets and advises swallowing them whole. It also includes an NDC code of 59212-200-10, a unique identifier for drugs. There is no other useful information provided.*

FDA Label Image

Bottle 30tablets

This is a description for a medication named Uroxatral, containing alfuzosin HCl 10mg. The medication is supplied in a bottle of 30 tablets that should be swallowed whole and not chewed or crushed. The package insert should be consulted for dosage information, and the medication should be stored in a dry and cool place away from kids. The NDC number for this medication is 59212-200-30.*

FDA Label Image

Chemical Structure (Image 01)

FDA Label Image

Figure 1 (Image 02)

FDA Label Image

Figure 2 (Image 03)

This text appears to be a graph or chart showing the mean change in some variable over time (28, 56, and 8 days) for two groups: a placebo group with 167 participants and a group treated with a medication called Uroxatral with 170 participants. The numbers likely correspond to the amount of change observed in the variable. However, without additional information, the meaning of the variable and the significance of the results cannot be determined.*

FDA Label Image

Figure 3 (Image 04)

The text describes the mean change observed in two groups of individuals during 28 days of treatment with a placebo and Uroxatral. The treatment resulted in a significant difference between the two groups (p<0.01).*

FDA Label Image

Figure 4 (Image 05)

FDA Label Image

Figure 5 (Image 06)

FDA Label Image

Figure 6 (Image 07)

FDA Label Image

Figure 7 (Image 08)

The data table shows the mean change in mL/s for a treatment group (UROXATRAL) compared to a placebo group over a period of 8 days. The treatment group showed a decrease of 4 mL/s, but this change was not statistically significant (p>0.05) compared to the placebo group.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.